RecruitingCystic Fibrosis
BEGIN Novel ImagiNG Biomarkers
Eligible age
6–8 yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
To determine the treatment effect of triple-combination therapy in 6-8 year olds after presumed FDA approval, using rapid structural and functional pulmonary and abdominal MRI (UTE and 129Xe).
Sponsor: Children's Hospital Medical Center, Cincinnati
You may qualify if…
- ✓ 1. Written informed consent (and assent where appropriate) obtained from the subject or subject's legal representative.
- ✓ 2. Willingness to adhere to the study-visit schedule and other protocol requirements.
- ✓ 3. Ages 6-8 years old at baseline MRI visit (may be enrolled up to 60 days before 6th birthday).
- ✓ 4. Documentation of CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
- ✓ 1. Sweat chloride equal to or greater than 60 mEq/liter by quantitative pilocarpine iontophoresis test
- ✓ 2. Two well-characterized mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
- ✓ 5. Physician intent to prescribe triple-combination therapy
- ✓ 6. Clinically-stable with no respiratory tract infection at the time of enrollment.
You may not qualify if…
- ✕ 1. Individuals currently on ivacaftor therapy (including Kalydeco, Orkambi, and Symdeko) and with at least one gating mutation. Gating mutations include G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, or G1349D.
- ✕ 2. Acute respiratory symptoms (e.g. wheezing) at the time of the MRI.
- ✕ 3. Acute respiratory infection, defined as increased cough, wheezing or respiratory rate in the 28 days prior to enrollment.
- ✕ 4. Chronic lung disease not related to CF
- ✕ 5. Chronic liver disease not related to CF
- ✕ 6. Acute pancreatitis, defined by clinical criteria (45).
- ✕ 7. Chronic pancreatic disease not related to CF.
- ✕ 8. Physical findings that would compromise the safety of the subject or the quality of the study data as determined at the discretion of the site investigator.
Where it's recruiting
Source: ClinicalTrials.gov · NCT05517655 · last updated 2024-11-21